This study is comparing the efficacy of the study drug RO7198457 versus “watchful waiting” in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

The purpose of this study is to test the efficacy of the combination of the study drugs tazemetostat with mosunetuzumab and see what effects it has on untreated follicular lymphoma. An additional purpose of this study is to understand what side effects people may have when they receive both drugs together.

This is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration resistant prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled.

This clinical trial is for men and women with Clonal Cytopenia of Undetermined Significance (CCUS).

The purpose of this research is to test the benefit and safety of Canakinumab. Canakinumab is experimental, which means that they are being tested and are not yet approved by the United States Food and Drug Administration (FDA).

This clinical trial is for men and women with early-stage esophageal cancer (EC) or gastroesophageal junction cancer (GEJC) who are currently receiving adjuvant nivolumab prior to and independently of participation in the study.

The purpose of this study is to learn more about patients with EC or GEJC who have started with nivolumab treatment and about the use and the effects of nivolumab in clinical practice. For this reason, BMS is conducting this study to collect additional information about:

This clinical trial is for men and women who have myeloid disease, a disease caused by blood cells that are not working properly.
   

The purpose of this study is to help us learn how best to support young women making decisions about breast cancer surgery.

Over the course of this study, a web-based decision support tool (“CONSYDER”) designed for women between the ages of 18-44 who are newly diagnosed with breast cancer and making decisions about breast cancer surgery, will begin to be offered as standard of care at each study site. Because sites will be provided access to CONSYDER at different times, some study participants will have access to the tool while others will not.

Doctors know a lot about performing prostate surgeries. However, we are always trying to learn more and improve our skills for our patients' benefit. We want to try and make prostate surgeries safer, with fewer side effects for the patient, and look for a better way to remove cancer. In this study, we will monitor if there are problems after a participant's surgery. We will also document the results of the surgery and patient-reported quality of life.

The purpose of this registry is to collect subject data, medical information, treatment data, and outcomes of patients treated by the Head and Neck Surgery Division in the Department of Otolaryngology at New York Presbyterian Hospital/Weill Cornell Medical Center. The intended use of this database is for research related to the evaluation, management, and outcomes of patients who were treated by our providers.

This study is designed to explore whether we can use the same images obtained at simulation to potentially screen for abnormal lung or heart imaging findings.